New Protocols (11*)
* The protocols may appear repeatedly under different diseasesNHL, B-Cell Type, Diffuse Large Cell
- Brentuximab Vedotin 1.2 / Rituximab 375 / Lenalidomide 20, diffuse large B-Non-Hodgkin Lymphoma PID 2906 V1.0 (2025-05-08)
- Odronextamab (0.2/0.5/2/10), diffuse large cell non-Hodgkin Lymphoma, cycle 1 PID 2886 V1.0 (2025-05-07)
- Odronextamab 160, diffuse large cell non-Hodgkin Lymphoma, cycle 2 PID 2893 V1.0 (2025-05-07)
- Odronextamab 160, diffuse large cell non-Hodgkin Lymphoma, cycle 3-4 PID 2894 V1.0 (2025-05-07)
- Odronextamab 320, diffuse large cell non-Hodgkin Lymphoma, cycle 2 weeks PID 2895 V1.0 (2025-05-07)
- Odronextamab 320, diffuse large cell non-Hodgkin Lymphoma, maintenance 4 weeks PID 2896 V1.0 (2025-05-07)
NHL, B-Cell Type, Follicular Grade I-IIIa
- Odronextamab (0.2/0.5/2/10), follicular Lymphoma °I-IIIa, cycle 1 PID 2897 V1.0 (2025-05-12)
- Odronextamab 80, follicular Lymphoma °I-IIIa, cycle 2 PID 2898 V1.0 (2025-05-12)
- Odronextamab 80, follicular Lymphoma ° I-IIIa, cycle 3-4 PID 2899 V1.0 (2025-05-12)
- Odronextamab 160, follicular Lymphoma °I-IIIa, maintenance 2 weeks PID 2900 V1.0 (2025-05-12)
- Odronextamab 160, follicular Lymphoma °I-IIIa, maintenance 4 weeks PID 2901 V1.0 (2025-05-12)
Updated Protocols (0*)
* The protocols may appear repeatedly under different diseasesProtocols in Revision
Lung Carcinoma, Small Cell
- ACO II - Doxorubicin 60 / Cyclophosphamide 750 / Vincristine 1.5, Small Cell Lung Carcinoma PID 218 V2.0
Multiple Myeloma
- Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 1 PID 41 V1.2
- Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20 / Isatuximab 10, multiple myeloma, induction, IB, cycle 2-3 PID 42 V1.2
